3 active not recruiting, 1 completed, 1 recruiting. 5 Phase 3, 1 Phase 2.
By phase and status
Follow tafasitamab: new trials by email Literature Review of tafasitamab trials Research Report on tafasitamab
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Tafasitamab, Lenalidomide, Gemcitabine - DLBCL | Phase 3 | Recruiting | 244 | 2024-05-07 | 2024-07-25 |
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Tafasitamab, Lenalidomide - Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | 82 | 2022-12-23 | 2026-10-22 |
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | 899 | 2021-05-11 | 2026-04-01 |
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
tafasitamab, rituximab, lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Active not recruiting | 654 | 2021-04-15 | 2026-09-04 |
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Rituximab (RTX), Tafasitamab, Bendamustine (BEN) - Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Completed | 453 | 2016-11-28 | 2025-07-17 |
Conditions studied
Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1)
Sponsors
Incyte Corporation (4) · Beijing InnoCare Pharma Tech Co., Ltd. (1)
Countries
Czechia (4) · Hungary (4) · Israel (4) · Poland (4) · Turkey (Türkiye) (4) · United Kingdom (4) · Australia (3) · Austria (3) · Canada (3) · Finland (3) · France (3) · Germany (3) · Ireland (3) · Italy (3) · Romania (3)
Top investigators
Oliver Manzke, MD (1)
Results publications
PMID 37369099, PMID 39319495, PMID 40993016, PMID 41360064, PMID 42217458
NIH funding
2023 (2), 2014 (1)